Skip to main content
Premium Trial:

Request an Annual Quote

Two Blades Partners With Sainsbury Laboratory, JR Simplot on Potato Disease Resistance

NEW YORK (GenomeWeb News) – The Two Blades Foundation today announced that it has formed a research partnership with the Sainsbury Laboratory and ag-bio firm JR Simplot to develop potato varieties with increased resistance to oomycete and bacterial diseases.

Oomycete diseases are fungal infections that include late blight, the disease responsible for the Irish Potato Famine and one that still causes significant yield losses today. Bacterial diseases such as bacterial wilt and soft rot, meanwhile, threaten potato plants in the field and stored potatoes. 

2Blades and its collaborators will investigate new sources of late blight resistance previously identified at the Sainsbury Laboratory. They will also work to identify new disease-resistance genes that can be incorporated into next-generation versions of Simplot's Innate potatoes, which are modified to resist common North American strains of late blight.

The partners will also test the ability of EFR, a broad-spectrum immune receptor that recognizes bacteria, to protect potatoes from a variety of bacterial diseases. Researchers at the Sainsbury Laboratory have demonstrated that the gene can confer bacterial infection resistance in tomato, tobacco, wheat, and other crops.

"The partnership with 2Blades and the Sainsbury Laboratory combines some of the most promising technology to combat devastating diseases with the popular commercial varieties of potatoes," Craig Richael, director of R&D at Simplot Plant Sciences, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.